News By: Gary Cramer

This article explores strategies to improve study start-up efficiency, including best practices in site feasibility, regulatory submissions, contract negotiations, and communication. It also examines the use of performance metrics, parallel processing, and technology-driven solutions to accelerate trial initiation without compromising quality.

The goal of the revised ICH E6(R3) guideline for Good Clinical Practice is to drive stronger governance, continuous quality advancement, and consistent study collaboration globally. To meet the new expectations, sponsors, sites, and contract research organizations should consider revising procedures, systems, and training programs for proactive oversight.

Modernizing the legacy systems of the clinical research enterprise can’t wait for the next advancement. By migrating legacy systems to cloud-based architectures, trial data can be logged more accurately, timelines can be improved, and opportunities for advancement can be better realized.

Even with strong protocols and qualified investigators, many clinical trials experience delays that have nothing to do with science. Instead, they originate from administrative weaknesses that quietly slow progress, inflate costs, and strain research staff. Let’s look at the administrative weaknesses that most often impede the efficiency of trials, along with practical solutions that can be put in place by organizations to enhance their performance and protect study timelines.

Patient safety, credible data, and the investigator’s responsibilities are equally important, but the investigator’s responsibilities are the most actionable, and help drive patient safety and credible data. They are also best facilitated by strong, professional relationships between investigators and other members of the clinical trials team.